Base de dados : MEDLINE
Pesquisa : D05.500.945.925 [Categoria DeCS]
Referências encontradas : 6441 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 645 ir para página                         

  1 / 6441 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Abreu, Glaucia Rodrigues
Texto completo
[PMID]:29381962
[Au] Autor:Silva FB; Romero WG; Carvalho ALRA; Souza GAA; Claudio ERG; Abreu GR
[Ad] Endereço:Department of Physiological Sciences.
[Ti] Título:Effects of treatment with chemotherapy and/or tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer.
[So] Source:Medicine (Baltimore);96(47):e8723, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There has been an increase in deaths from cardiovascular diseases following breast cancer therapy. Evidence has shown that this outcome is, in part, associated with cardiotoxicity induced by the chemotherapeutic drugs and the increase in oxidative stress. The aim of this study was to evaluate the effects of chemotherapy and hormone therapy with tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer.Thirty women were followed-up for 1 year and were divided into 3 groups according to the treatment protocol: women treated only with tamoxifen and clinical follow up for 12 months (Tam, n = 10); women treated only with chemotherapy for 6 months with clinical follow up for an additional 6-month period (Chemo, n = 10); and women who received chemotherapy for 6 months followed by a 6-month period only with tamoxifen therapy and clinical follow up (Chemo + Tam, n = 10). Analysis of the blood levels of cardiac troponin I (cTnI), advanced oxidation protein products (AOPP) and the activity of the plasmatic isoform of the antioxidant enzyme glutathione peroxidase (GPx) was performed before treatment (T0) and at 6 (T6) and 12 (T12) months after treatment.The Chemo group showed higher levels of cTnI (0.065 ±â€Š0.006 ng/mL, P < .05) and AOPP (4.99 ±â€Š0.84 µmol/L, P < .05) and reduced GPx activity (24.4 ±â€Š1.1 nM/min/mL, P < .05) at T12 than the Tam group (cTnI: 0.031 ±â€Š0.001 ng/mL; AOPP: 1.40 ±â€Š0.10 µmol/L; GPx: 28.0 ±â€Š0.7 nM/min/mL) and Chemo + Tam group (cTnI: 0.037 ±â€Š0.002 ng/mL; AOPP: 2.53 ±â€Š0.30 µmol/L; GPx: 29.5 ±â€Š1.0 nM/min/mL).These data support the hypothesis that long-term oxidative stress after chemotherapy may have an impact on cardiovascular diseases and that tamoxifen has cardioprotective effects.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Neoplasias da Mama/tratamento farmacológico
Doenças Cardiovasculares/induzido quimicamente
Estresse Oxidativo/efeitos dos fármacos
Tamoxifeno/efeitos adversos
[Mh] Termos MeSH secundário: Produtos da Oxidação Avançada de Proteínas/sangue
Antineoplásicos/uso terapêutico
Biomarcadores
Feminino
Glutationa Peroxidase/sangue
Seres Humanos
Meia-Idade
Tamoxifeno/uso terapêutico
Fatores de Tempo
Troponina I/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Advanced Oxidation Protein Products); 0 (Antineoplastic Agents); 0 (Biomarkers); 0 (Troponin I); 094ZI81Y45 (Tamoxifen); EC 1.11.1.9 (Glutathione Peroxidase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008723


  2 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258067
[Au] Autor:Gao L; Liu Y; Guo S; Yao R; Wu L; Xiao L; Wang Z; Liu Y; Zhang Y
[Ti] Título:Circulating Long Noncoding RNA HOTAIR is an Essential Mediator of Acute Myocardial Infarction.
[So] Source:Cell Physiol Biochem;44(4):1497-1508, 2017.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Acute myocardial infarction (AMI) is one of the leading causes of death in the world. However, specific diagnostic biomarkers have not been fully determined, and candidate regulatory targets for AMI have not been identified to date. Long noncoding RNAs (lncRNAs) are a class of RNA molecules that have diverse regulatory functions during embryonic development, normal life, and disease in higher organisms. However, research on the role of lncRNAs in cardiovascular diseases, particularly AMI, is still in its infancy. HOX antisense intergenic RNA (HOTAIR), a 2.2 kb lncRNA, was initially described as a modulator of HOX gene expression. Recent studies have illustrated the important role of HOTAIR in cancer progression, but few studies have reported its function in cardiac disease, including AMI. In the current study, we aimed to detect the expression of HOTAIR during AMI and to explore its function in hypoxia-induced cardiomyocyte injury in neonatal cardiomyocytes. METHODS: In 50 consecutively enrolled AMI patients, we examined the serum expression levels of HOTAIR and analysed its correlation with cardiac troponin I (cTnI) expression. Another 50 age- and sex-matched subjects served as healthy controls. Next, the HOTAIR expression was detected in the serum from C57BL/6J mice subjected to coronary artery ligation and in neonatal rat cardiomyocytes induced by hypoxia. Cultured cardiomyocytes apoptosis were measured by terminal deoxynucleotide transferase dUTP nick end labelling (TUNEL) staining. A search for miRNAs that had complementary base paring with HOTAIR was performed utilizing an online software program, and the interaction between miR-1 and HOTAIR was examined using a luciferase reporter assay. RESULTS: Our study revealed that HOTAIR expression was significantly decreased in the serum of AMI patients compared with that of the healthy controls. Similarly, we observed that HOTAIR was downregulated in the serum of mice subjected to coronary artery ligation and in cultured cardiomyocytes exposed to hypoxia. Furthermore, we observed that the adenovirus vector-driven overexpression of HOTAIR dramatically limited hypoxia-induced myocyte apoptosis, whereas knockdown HOTAIR by AdshHOTAIR (adenoviral short hairpin HOTAIR) exhibited the opposite phenotype. Mechanistically, we discovered that the cardioprotective function of HOTAIR is partly based on the negative regulation of miR-1. CONCLUSIONS: Taken together, the results of our study suggest that HOTAIR is a protective factor for cardiomyocytes and that the plasma concentration of HOTAIR may serve as a biomarker for human AMI diagnosis.
[Mh] Termos MeSH primário: Infarto do Miocárdio/sangue
RNA Longo não Codificante/sangue
[Mh] Termos MeSH secundário: Idoso
Animais
Apoptose
Biomarcadores/sangue
Hipóxia Celular
Feminino
Seres Humanos
Masculino
Camundongos
Meia-Idade
Infarto do Miocárdio/diagnóstico
Infarto do Miocárdio/patologia
Miócitos Cardíacos/metabolismo
Miócitos Cardíacos/patologia
Ratos
Troponina I/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (HOTAIR long non-coding RNA, mouse); 0 (HOTAIR long untranslated RNA, human); 0 (HOTAIR long untranslated RNA, rat); 0 (RNA, Long Noncoding); 0 (Troponin I)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180102
[Lr] Data última revisão:
180102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE
[do] DOI:10.1159/000485588


  3 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29182678
[Au] Autor:Wilke P; Masuch A; Fahron O; Zylla S; Leipold T; Petersmann A
[Ad] Endereço:Central Emergency Department, Klinikum Frankfurt (Oder) GmbH, Rhön AG, Frankfurt (Oder), Germany.
[Ti] Título:Diagnostic performance of point-of-care and central laboratory cardiac troponin assays in an emergency department.
[So] Source:PLoS One;12(11):e0188706, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Early diagnosis of myocardial infarction (MI) with cardiac troponin (cTn) assays at the point-of-care (POC) is suggested to shorten turn-around-time in the emergency department (ED). The present study aimed at comparing the diagnostic performance of two POC cTn assays with that of a central laboratory high-sensitivity (hs) method, under routine ED conditions. In 2,163 non-selected ED patients suspected for MI, the diagnostic performance of the POC troponin I (TnI), troponin T (TnT), and hs-TnT assay for the prediction of MI was evaluated based on receiver operating characteristic (ROC) analyses and compared with the performance based on the manufacturers' cut-offs. Due to an observed association between renal function as determined by estimated glomerular filtration rate (eGFR) and cTn concentrations, all analyses were stratified by renal function. In patients with normal renal function (eGFR > 60 mL/min/1.73m2), POC and hs assays showed a comparable diagnostic performance as quantified by the area under the ROC curve (AUC) of about 0.88. The ROC-derived optimal cut-off (OCO) levels for the different cTn assays clearly changed with decreasing kidney function. Impaired kidney function required OCO to be three to five times higher to achieve a comparable performance. Particularly cTnT concentrations were strongly associated with renal function. The three cTn assays demonstrated equivalent diagnostic performance in ED-patients admitted with suspected ACS in relation to the release diagnosis, supporting the use of POC testing in this setting. The present results implicate that application of eGFR-specific OCOs may decrease false-positives among patients with impaired renal function. Providing individual cut-offs depending on patients' eGFR might be an appropriate add-on tool to improve specificity in the diagnosis of MI.
[Mh] Termos MeSH primário: Serviço Hospitalar de Emergência
Infarto do Miocárdio/diagnóstico
Sistemas Automatizados de Assistência Junto ao Leito
Troponina I/sangue
Troponina T/sangue
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Feminino
Seres Humanos
Laboratórios Hospitalares
Masculino
Meia-Idade
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Troponin I); 0 (Troponin T)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188706


  4 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464239
[Au] Autor:Jumabay M; Zhumabai J; Mansurov N; Niklason KC; Guihard PJ; Cubberly MR; Fogelman AM; Iruela-Arispe L; Yao Y; Saparov A; Boström KI
[Ad] Endereço:Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, California.
[Ti] Título:Combined effects of bone morphogenetic protein 10 and crossveinless-2 on cardiomyocyte differentiation in mouse adipocyte-derived stem cells.
[So] Source:J Cell Physiol;233(3):1812-1822, 2018 Mar.
[Is] ISSN:1097-4652
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bone morphogenetic protein (BMP) 10, a cardiac-restricted BMP family member, is essential in cardiomyogenesis, especially during trabeculation. Crossveinless-2 (CV2, also known as BMP endothelial cell precursor derived regulator [BMPER]) is a BMP-binding protein that modulates the activity of several BMPs. The objective of this study was to examine the combined effects of BMP10 and CV2 on cardiomyocyte differentiation using mouse dedifferentiated fat (mDFAT) cells, which spontaneously differentiate into cardiomyocyte-like cells, as a model. Our results revealed that CV2 binds directly to BMP10, as determined by co-immunoprecipitation, and inhibits BMP10 from initiating SMAD signaling, as determined by luciferase reporter gene assays. BMP10 treatment induced mDFAT cell proliferation, whereas CV2 modulated the BMP10-induced proliferation. Differentiation of cardiomyocyte-like cells proceeded in a reproducible fashion in mDFAT cells, starting with small round Nkx2.5-positive progenitor cells that progressively formed myotubes of increasing length that assembled into beating colonies and stained strongly for Troponin I and sarcomeric alpha-actinin. BMP10 enhanced proliferation of the small progenitor cells, thereby securing sufficient numbers to support formation of myotubes. CV2, on the other hand, enhanced formation and maturation of large myotubes and myotube-colonies and was expressed by endothelial-like cells in the mDFAT cultures. Thus BMP10 and CV2 have important roles in coordinating cardiomyogenesis in progenitor cells.
[Mh] Termos MeSH primário: Proteínas Morfogenéticas Ósseas/metabolismo
Proteínas de Transporte/metabolismo
Diferenciação Celular/fisiologia
Miócitos Cardíacos/citologia
Células-Tronco/citologia
[Mh] Termos MeSH secundário: Actinina/metabolismo
Adipócitos/citologia
Animais
Proliferação Celular
Células Cultivadas
Proteína Homeobox Nkx-2.5/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Transdução de Sinais/fisiologia
Proteínas Smad/metabolismo
Troponina I/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bmp10 protein, mouse); 0 (Bone Morphogenetic Proteins); 0 (Carrier Proteins); 0 (Homeobox Protein Nkx-2.5); 0 (Nkx2-5 protein, mouse); 0 (Smad Proteins); 0 (Troponin I); 0 (crossveinless 2 protein, mouse); 11003-00-2 (Actinin)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1002/jcp.25983


  5 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449360
[Au] Autor:Winter RL; Saunders AB; Gordon SG; Miller MW; Fosgate GT; Suchodolski JS; Steiner JM
[Ad] Endereço:Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA.
[Ti] Título:Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.
[So] Source:Vet Clin Pathol;46(2):299-307, 2017 Jun.
[Is] ISSN:1939-165X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Biologic variability (BV) is one aspect of interpreting changes in biomarker concentrations known to be clinically important in people with cardiac disease, but it has not been adequately addressed in dogs so far. OBJECTIVES: The purpose of the study was to determine BV of cardiac troponin I (cTnI) in healthy dogs and dogs with 3 stages of myxomatous mitral valve disease (MMVD). METHODS: Healthy dogs and dogs with 3 stages of MMVD were prospectively assigned to groups based on comprehensive clinical evaluation using current guidelines. Concentrations of cTnI were measured hourly, daily, and weekly using standard and high-sensitivity immunoassays. Within- (CV ) and between-subject (CV ) coefficients of variability, percent reference change value (RCV), and index of individuality (IoI) were calculated. RESULTS: All 10 healthy dogs and 76/112 (68%) of samples from 28 MMVD dogs had cTnI concentrations below the limit of detection (LOD) using a standard sensitivity immunoassay. Only 49/160 (31%) of healthy dog samples and no MMVD samples had cTnI below the high-sensitivity immunoassay LOD. Data analysis for the high-sensitivity immunoassay revealed CV of 48.1%, CV of 60.1%, RCV of 134.0%, and IoI of 0.804 in healthy dogs. In MMVD dogs, CV was 39.6%, CV was 80.7%, RCV was 110%, and IoI was 0.494. Of all MMVD dogs, those with Stage B2 had the lowest RCV of 91%. CONCLUSIONS: Biologic variability affects cTnI concentrations in healthy dogs and dogs with MMVD. Consideration of BV may be clinically relevant when monitoring individual changes in cTnI values, using high-sensitivity immunoassays.
[Mh] Termos MeSH primário: Doenças do Cão/sangue
Insuficiência da Valva Mitral/veterinária
Troponina I/sangue
[Mh] Termos MeSH secundário: Animais
Variação Biológica Individual
Variação Biológica da População
Biomarcadores/sangue
Estudos de Casos e Controles
Cães/sangue
Feminino
Imunoensaio/veterinária
Masculino
Insuficiência da Valva Mitral/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Troponin I)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1111/vcp.12495


  6 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29114078
[Au] Autor:Shah ASV; Sandoval Y; Noaman A; Sexter A; Vaswani A; Smith SW; Gibbins M; Griffiths M; Chapman AR; Strachan FE; Anand A; Denvir MA; Adamson PD; D'Souza MS; Gray AJ; McAllister DA; Newby DE; Apple FS; Mills NL
[Ad] Endereço:BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4SB, UK.
[Ti] Título:Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study.
[So] Source:BMJ;359:j4788, 2017 Nov 07.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo: To evaluate how selection of patients for high sensitivity cardiac troponin testing affects the diagnosis of myocardial infarction across different healthcare settings. Prospective study of three independent consecutive patient populations presenting to emergency departments. Secondary and tertiary care hospitals in the United Kingdom and United States. High sensitivity cardiac troponin I concentrations were measured in 8500 consecutive patients presenting to emergency departments: unselected patients in the UK (n=1054) and two selected populations of patients in whom troponin testing was requested by the attending clinician in the UK (n=5815) and the US (n=1631). The final diagnosis of type 1 or type 2 myocardial infarction or myocardial injury was independently adjudicated. Positive predictive value of an elevated cardiac troponin concentration for a diagnosis of type 1 myocardial infarction. Cardiac troponin concentrations were elevated in 13.7% (144/1054) of unselected patients, with a prevalence of 1.6% (17/1054) for type 1 myocardial infarction and a positive predictive value of 11.8% (95% confidence interval 7.0% to 18.2%). In selected patients, in whom troponin testing was guided by the attending clinician, the prevalence and positive predictive value were 14.5% (843/5815) and 59.7% (57.0% to 62.2%) in the UK and 4.2% (68/1631) and 16.4% (13.0% to 20.3%) in the US. Across both selected patient populations, the positive predictive value was highest in patients with chest pain, with ischaemia on the electrocardiogram, and with a history of ischaemic heart disease. When high sensitivity cardiac troponin testing is performed widely or without previous clinical assessment, elevated troponin concentrations are common and predominantly reflect myocardial injury rather than myocardial infarction. These observations highlight how selection of patients for cardiac troponin testing varies across healthcare settings and markedly influences the positive predictive value for a diagnosis of myocardial infarction.
[Mh] Termos MeSH primário: Infarto do Miocárdio/sangue
Seleção de Pacientes
Troponina I/sangue
[Mh] Termos MeSH secundário: Serviço Hospitalar de Emergência
Feminino
Seres Humanos
Masculino
Meia-Idade
Infarto do Miocárdio/epidemiologia
Valor Preditivo dos Testes
Prevalência
Estudos Prospectivos
Sensibilidade e Especificidade
Reino Unido/epidemiologia
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Troponin I)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171119
[Lr] Data última revisão:
171119
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171109
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j4788


  7 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29030372
[Au] Autor:Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
[Ad] Endereço:From the Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH (R.M., J.L., C.Y.D., J.E.S.); Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA (K.S.G); Department of Horticulture Sciences, IFAS,
[Ti] Título:Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
[So] Source:Circ Heart Fail;10(10), 2017 Oct.
[Is] ISSN:1941-3297
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding the myosin cross-bridges (XBs) in the sarcomere. However, the mechanistic details governing OM-induced modulation of XB behavior in failing human myocardium are unclear. METHODS AND RESULTS: The effects of OM on steady state and dynamic XB behavior were measured in chemically skinned myocardial preparations isolated from human donor and heart failure (HF) left ventricle. HF myocardium exhibited impaired contractile function as evidenced by reduced maximal force, magnitude of XB recruitment ( ), and a slowed rate of XB detachment ( ) at submaximal Ca activations. Ca sensitivity of force generation (pCa ) was higher in HF myocardium when compared with donor myocardium, both prior to and after OM incubations. OM incubation (0.5 and 1.0 µmol/L) enhanced force generation at submaximal Ca activations in a dose-dependent manner. Notably, OM induced a slowing in with 1.0 µmol/L OM but not with 0.5 µmol/L OM in HF myocardium. Additionally, OM exerted other differential effects on XB behavior in HF myocardium as evidenced by a greater enhancement in and slowing in the time course of cooperative XB recruitment ( ), which collectively prolonged achievement of peak force development ( ), compared with donor myocardium. CONCLUSIONS: Our findings demonstrate that OM augments force generation but also prolongs the time course of XB transitions to force-bearing states in remodeled HF myocardium, which may extend the systolic ejection time in vivo. Optimal OM dosing is critical for eliciting enhanced systolic function without excessive prolongation of systolic ejection time, which may compromise diastolic filling.
[Mh] Termos MeSH primário: Cardiotônicos/farmacologia
Insuficiência Cardíaca/tratamento farmacológico
Força Muscular/efeitos dos fármacos
Contração Miocárdica/efeitos dos fármacos
Miosinas/metabolismo
Ureia/análogos & derivados
[Mh] Termos MeSH secundário: Cardiotônicos/metabolismo
Proteínas de Transporte/metabolismo
Estudos de Casos e Controles
Relação Dose-Resposta a Droga
Insuficiência Cardíaca/metabolismo
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Técnicas In Vitro
Fosforilação
Ligação Proteica
Sarcômeros/metabolismo
Transdução de Sinais/efeitos dos fármacos
Fatores de Tempo
Troponina I/metabolismo
Troponina T/metabolismo
Ureia/metabolismo
Ureia/farmacologia
Remodelação Ventricular
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Carrier Proteins); 0 (Troponin I); 0 (Troponin T); 0 (myosin-binding protein C); 2M19539ERK (omecamtiv mecarbil); 8W8T17847W (Urea); EC 3.6.4.1 (Myosins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171015
[St] Status:MEDLINE


  8 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29019905
[Au] Autor:Yuan KM; Fu SY; Li J; Shangguan WN; Lian QQ
[Ad] Endereço:Department of Anesthesiology and Perioperative Medicine, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
[Ti] Título:Bezold-Jarisch reflex occurred in a pediatric patient with giant intra-abdominal teratoma during induction of anesthesia: A case report.
[So] Source:Medicine (Baltimore);96(41):e8304, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Bezold-Jarisch reflex (BJR) occurs when the cardioinhibitory receptors in the walls of ventricles are activated by various stimuli, with typical features of bradycardia, vasorelaxation, and hypotension. This reflex usually happens in parturient intrathecal anesthesia, as a result of decreased venous return by compression of inferior vena cava, but it is only rarely reported during general anesthesia. PATIENT CONCERNS: Severe bradycardia and hypotension, indicating BJR, occurred during the induction of general anesthesia in a 3-month-old female child with giant intra-abdominal teratoma. DIAGNOSES: A giant intra-abdominal teratoma was detected by computed tomography scanning. The decreased left ventricular ejection faction along with increased troponin I and N-terminal pro-B-type natriuretic peptide indicated a preoperative mild cardiac dysfunction. BJR was diagnosed on the basis of the severe bradycardia and hypotension observed during the induction of general anesthesia, INTERVENTIONS:: Atropine failed to increase heart rate. Cardiopulmonary resuscitation was initiated immediately and epinephrine was injected intravenously because of sudden circulatory collapse. Soon after the return of spontaneous circulation, a central venous line was placed and invasive blood pressure was monitored. Vital signs and homeostasis were kept stable during teratoma resection. OUTCOMES: The child was extubated after emergence from anesthesia in the operating room. Eleven days later, she had recovered without complications and was discharged. LESSONS: General anesthesia should be induced with great care in patients with giant intra-abdominal masses, and the patient should be kept in the left-lateral table tilt position before induction.
[Mh] Termos MeSH primário: Neoplasias Abdominais
Bradicardia
Dissecação/métodos
Hipotensão
Teratoma
Vasodilatação/fisiologia
[Mh] Termos MeSH secundário: Neoplasias Abdominais/patologia
Neoplasias Abdominais/fisiopatologia
Neoplasias Abdominais/cirurgia
Bradicardia/diagnóstico
Bradicardia/etiologia
Reanimação Cardiopulmonar/métodos
Feminino
Seres Humanos
Hipotensão/diagnóstico
Hipotensão/etiologia
Lactente
Peptídeo Natriurético Encefálico/análise
Fragmentos de Peptídeos/análise
Reflexo Anormal
Volume Sistólico
Teratoma/patologia
Teratoma/fisiopatologia
Teratoma/cirurgia
Tomografia Computadorizada por Raios X/métodos
Resultado do Tratamento
Troponina I/análise
Carga Tumoral
Disfunção Ventricular Esquerda/diagnóstico
Disfunção Ventricular Esquerda/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Peptide Fragments); 0 (Troponin I); 0 (pro-brain natriuretic peptide (1-76)); 114471-18-0 (Natriuretic Peptide, Brain)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171122
[Lr] Data última revisão:
171122
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008304


  9 / 6441 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28972002
[Au] Autor:Kaier TE; Twerenbold R; Puelacher C; Marjot J; Imambaccus N; Boeddinghaus J; Nestelberger T; Badertscher P; Sabti Z; Giménez MR; Wildi K; Hillinger P; Grimm K; Loeffel S; Shrestha S; Widmer DF; Cupa J; Kozhuharov N; Miró Ò; Martín-Sánchez FJ; Morawiec B; Rentsch K; Lohrmann J; Kloos W; Osswald S; Reichlin T; Weber E; Marber M; Mueller C
[Ad] Endereço:From King's College London BHF Centre, Rayne Institute, St Thomas' Hospital, London, UK (T.K., J.M., N.I., M.M.); Department of Cardiology and Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland (R.T., C.P., J.B., T.N., P.B., Z.S., M.R.G., K.W., P.H., K.G., S.L., S.S., D.
[Ti] Título:Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction.
[So] Source:Circulation;136(16):1495-1508, 2017 Oct 17.
[Is] ISSN:1524-4539
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly after acute myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to cTn in the early diagnosis of AMI. METHODS: Unselected patients (N=1954) presenting to the emergency department with symptoms suggestive of AMI, concentrations of cMyC, and high-sensitivity (hs) and standard-sensitivity cTn were measured at presentation. The final diagnosis of AMI was independently adjudicated using all available clinical and biochemical information without knowledge of cMyC. The prognostic end point was long-term mortality. RESULTS: Final diagnosis was AMI in 340 patients (17%). Concentrations of cMyC at presentation were significantly higher in those with versus without AMI (median, 237 ng/L versus 13 ng/L, <0.001). Discriminatory power for AMI, as quantified by the area under the receiver-operating characteristic curve (AUC), was comparable for cMyC (AUC, 0.924), hs-cTnT (AUC, 0.927), and hs-cTnI (AUC, 0.922) and superior to cTnI measured by a contemporary sensitivity assay (AUC, 0.909). The combination of cMyC with hs-cTnT or standard-sensitivity cTnI (but not hs-cTnI) led to an increase in AUC to 0.931 ( <0.0001) and 0.926 ( =0.003), respectively. Use of cMyC more accurately classified patients with a single blood test into rule-out or rule-in categories: Net Reclassification Improvement +0.149 versus hs-cTnT, +0.235 versus hs-cTnI ( <0.001). In early presenters (chest pain <3 h), the improvement in rule-in/rule-out classification with cMyC was larger compared with hs-cTnT (Net Reclassification Improvement +0.256) and hs-cTnI (Net Reclassification Improvement +0.308; both <0.001). Comparing the C statistics, cMyC was superior to hs-cTnI and standard sensitivity cTnI ( <0.05 for both) and similar to hs-cTnT at predicting death at 3 years. CONCLUSIONS: cMyC at presentation provides discriminatory power comparable to hs-cTnT and hs-cTnI in the diagnosis of AMI and may perform favorably in patients presenting early after symptom onset. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT00470587.
[Mh] Termos MeSH primário: Proteínas de Transporte/sangue
Infarto do Miocárdio/sangue
Infarto do Miocárdio/diagnóstico
Troponina I/sangue
Troponina T/sangue
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Área Sob a Curva
Biomarcadores/sangue
Diagnóstico Precoce
Serviço Hospitalar de Emergência
Europa (Continente)
Feminino
Seres Humanos
Masculino
Meia-Idade
Infarto do Miocárdio/mortalidade
Infarto do Miocárdio/terapia
Valor Preditivo dos Testes
Prognóstico
Curva ROC
Reprodutibilidade dos Testes
Fatores de Tempo
Triagem
Regulação para Cima
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (Carrier Proteins); 0 (Troponin I); 0 (Troponin T); 0 (myosin-binding protein C)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171123
[Lr] Data última revisão:
171123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171004
[St] Status:MEDLINE
[do] DOI:10.1161/CIRCULATIONAHA.117.028084


  10 / 6441 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28906388
[Au] Autor:Yang CW; Li H; Thomas L; Ramos M; Liu PH; Roe T; Valadri R; Kiel MC; Su VY; Shi Q
[Ad] Endereço:aDepartment of Internal Medicine, The Wright Center for Graduate Medical Education (WCGME), Scranton bHematology & Oncology Associates of Northeast Pennsylvania cDepartment of Epidemiology, Harvard T.H. Chan School of Public Health dCommonwealth Health Physician Network Great Valley Cardiology eDepartment of Family Medicine, WCGME fDepartment of Science, Marywood University, Scranton, PA gFaculty of Medicine, National Yang-Ming University, Taipei, Taiwan.
[Ti] Título:Retrospective cause analysis of troponin I elevation in non-CAD patients: Special emphasis on sepsis.
[So] Source:Medicine (Baltimore);96(37):e8027, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Troponin I is one of the most commonly tested biochemical markers in the emergency room (ER) and in the hospital setting. Besides coronary artery disease (CAD), demand ischemia with underlying tachycardia, anemia, hypertensive emergency, congestive heart failure, kidney disease, sepsis, and pulmonary embolism have also been reported to cause troponin I elevations. Few reports have excluded patients with CAD, and no study has summarized the proportion of these factors relative to an increased troponin I level. METHODS: The aim of this retrospective study was to investigate the level of contribution of causative factors in troponin I elevation. Charts of patients tested for troponin I during an ER visit or during hospitalization were collected. Patients with known CAD, abnormal stress tests, cardiac catheterizations, or discharge without an adequate cardiac evaluation were excluded. Logistic regression was used to identify predictors of elevated troponin I levels. RESULTS: A total of 586 patients were investigated in this study. Age, hemoglobin (Hb), heart rate (HR), glomerularfiltration rate, atrial fibrillation, congestive heart failure (CHF), and sepsis were significant predictors of elevated troponin I by analysis in univariate logistic regression (all P < .001). In multivariate logistic regression, sepsis, CHF, age, Hb, and HR were independent predictors of troponin I (all P < .01). A simple clinical scoring system was generated with 1 score on patients with age ≥ 60, Hb < 10 g/dL, and HR ≥ 100 beats per minute (bpm). The prevalence of elevated troponin I was 4%, 16%, 38%, and 50% for patients with scores of 0, 1, 2, and 3, respectively. In patients without sepsis and CHF, the chances of elevated troponin I were 2%, 11%, 28%, and 43%. CONCLUSIONS: Sepsis was found to be the strongest independent cause of elevated troponin I levels in non-CAD patients. The scoring system composed of age, hemoglobin (Hb), and heart rate (HR) can assist clinical evaluation of elevated troponin I test in non-CAD patients.
[Mh] Termos MeSH primário: Cardiopatias/sangue
Sepse/sangue
Troponina I/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Doença da Artéria Coronariana
Feminino
Cardiopatias/diagnóstico
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Sepse/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Troponin I)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008027



página 1 de 645 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde